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1. INTRODUCTION 
The Protein kinase R (PKR), also called eukaryotic 
translation initiation factor 2-alpha kinase 2 (EIF2AK2), is 
an interferon-inducible double-stranded RNA protein 
kinase with multiple effects in cells (1, 2). PKR actively 
contributes to the cellular response to numerous types of 
stress, with a critical role in the antiviral defence 
mechanism of the host induced by interferons. Interferon 
cytokines (IFNs) have a wide range of biological 
functions, including antiviral, antiproliferative and 
immunomodulatory properties (3). The cloning of 
interferon genes, the structure of the ligand and their 
receptors, and the signalling pathways and transcription of 
IFN-induced genes have been instrumental in reaching an 
understanding of how these molecules exert their function 
in the cell (4, 5). Among the molecules with important 
biological function induced by IFN is PKR, which was 
discovered after the important observations carried out by 
the Metz and Kerr groups in the National Institute for 
Medical Research, London. In August 1972, an article by 
Dr Metz and Dr Esteban published in the Nature journal 
showed how viral RNA could be detected in cells 
pretreated with interferon and infected with vaccinia virus, 
and how protein synthesis ceased early after infection. 
They concluded that the effect of interferon must therefore 
be at the stage of translation rather than transcription (6). 
A few months later, Dr Kerr's group described the 
inhibition of viral encephalomyocarditis messenger 
ribonucleic acid translation in L-cell extracts (7). 
Subsequently, they showed the effect that the synthetic 
form of dsRNA (poly dIdC) had on translation (8). These 
seminal studies led to the identification in 1976 of a 
protein with dsRNA-dependent kinase activity involved in 
translation modulation (9). The kinase activity responsible 
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for inhibition was then under active search in different 
laboratories after the demonstration that a dsRNA-
dependent kinase could inhibit translation through 
phosphorylation of the alpha subunit of eukaryotic 
initiation factor 2 (eIF2α) in rabbit reticulocyte lysates 
(10). In addition to eIF2α, the kinase activity was found to 
phosphorylate a p68 protein in human cells and a p65 
protein in murine cells (11). The generation of polyclonal 
and monoclonal antibodies against the human p68 protein 
allowed determining that this was the kinase itself (12). To 
achieve its cloning, which was performed at the Pasteur 
Institute (13), this kinase first had to be purified by 
immunoaffinity with specific monoclonal antibodies (14). 
Then, the purified protein was injected into mice in 
presence of poly(A).poly(U) (15). Different names were 
given to this kinase, such as p68 protein kinase, DAI 
(Double stranded Activated Inhibitor), dsRNA-dependent 
protein kinase, and P1/eIF2α kinase, until the decision was 
made to give PKR a consensus name: Protein Kinase 
dsRNA-dependent (16). The human PKR gene consists of 
17 exons (whereas the mouse gene has 16) and is encoded 
from a single gene located on human chromosome 2p21-
22 and on mouse chromosome 17E2 (17). PKR, which is 
expressed constitutively in mammalian cells, has an IFN-
stimulated response element (ISRE) in its determined 
promoter, required for transcriptional induction by type I 
IFN, but also a kinase conserved sequence (KCS) motif 
with an important role in basal transcription in absence of 
cytokine tratment (18).  
Since these findings were made, PKR has been 
extensively studied to document its relevance as a first-line 
defence mechanism against infection and as regulator of 
cell growth, and more recently it has also been analysed 
for its role in metabolism, inflammatory processes, and 
age-related diseases. In fact, numerous pieces of original 
research and reviews regarding PKR action have been 
published over the years. My research about the 
mechanism of action of this kinase started in close 
collaboration with Dr Gil and co-workers in the group led 
by Dr Esteban at the National Centre for Biotechnology 
(from 2000 until 2008), and has provided key insights into 
the consequences that PKR activation has at the cellular 
level but also at the clinical and therapeutic levels. For this 
reason our group was invited to review the knowledge of 
PKR in 2006-2007 (1, 2). These reviews are being 
referenced by other studies looking into the mechanism of 
action and the clinical implications of this kinase in several 
pathologies. In fact, the reviews we published under the 
direction of Dr Esteban, with my contribution as the first 
author, in the journals Microbiology and Molecular 
Biology Reviews and Biochimie have been cited over 600 
times to this date (Scopus database).  
 The present review will perform a chronological 
account of our major contributions to the knowledge of the 
mechanisms of action and regulation of PKR, as well as 
the decisive contributions of several international groups. 
Specific mention will be made of the studies that the 
author leads at the University Hospital Complex of 
Granada (Instituto de Investigación Biosanitaria de 
Granada, ibs.GRANADA) since 2009, in the group 
currently directed by Dr Marchal, which show the 
importance that PKR has as a target of conventional 
chemotherapeutics and novel drugs. In addition, special 
consideration will be given to future studies necessary to 
validate its use as a biomarker and a therapeutic target in 
various pathologies.  
2. MECHANISME OF ACTION OF PKR 
PKR is a serine-threonine kinase composed of a kinase 
domain, shared by the other eukaryotic initiation factor 2α 
(eIF2 α) kinases: general control nonrepressed 2 
serine/threonine-protein kinase (GCN2), heme-regulated 
serine/threonine-protein kinase (HRI), and PKR-like 
endoplasmic reticulum kinase (PERK) (19). In addition, 
PKR has two dsRNA binding domains that constitute the 
regulatory domain (20). Although the main direct PKR 
activator is dsRNA (produced during infection by several 
viruses and detected at low doses in mammalian cells), 
PKR is also activated by a variety of forms of cellular 
stress described throughout the manuscript. PKR, in 
response to specific stress signals, is activated by 
autophosphorylation and leads to the phosphorylation of 
eIF-2α impairing its activity, which results in the inhibition 
of protein synthesis and the induction of apoptosis (1, 2). 
In addition to its translational regulatory function, PKR 
has a role in signal transduction and transcriptional control 
through the inhibitor of κB (IkB)/nuclear factor κB (NF-
κB) pathways. Furthermore, PKR is involved in various 
pathways that activate and engage a number of 
transcription factors controlling the expression of multiple 
genes, including interferon regulatory factor 1 (IRF-1), 
signal transducers and activators of transcription factors 
(STATs), mitogen-activated protein kinases (MAPKs), and 
p53, among others (1, 2). All these events indicate that 
PKR protein needs to be highly regulated. In fact, 
numerous studies have found PKR to be dysregulated in 
most cancers, neurodegenerative diseases, and other 
pathologies. 
The main mechanisms of PKR activation by dsRNA, as 
well as its effects on the inhibition of protein synthesis 
through the phosphorylation of eIF2α, had already been 
thoroughly characterised before the start of my research in 
the field. However, the mechanism by which PKR 
activation induces the activation of the transcription factor 
NF-kB was still in the early stages of research when I 
joined Dr Esteban's group, where we made, along with Dr 
Gil, Dr Alcami and co-workers, some key contributions. 
These researchs, along with those of other groups, will be 
discussed in the following sections 
2.1. PKR activation  
Although the main direct PKR activator is dsRNA, 
PKR is also activated by a variety of cellular stresses, 
including cytokine, calcium stress, oxidative stress, 
endoplasmic reticulum stress, lipo-stress, amyloid-β (Aβ) 
peptide accumulation, polyanions such as heparin, and 
several drugs among others (1, 2, 21, 22), or through the 
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PKR associated activator (PACT) (23, 24). PKR is also an 
intermediary in TLR signalling (25). PKR is engaged in 
dsRNA-activated TLR3 signalling, recruited by a TAK1-
containing complex in response to dsRNA binding to the 
TLR3 receptor. In addition, PKR integrates and transmits 
these signals not only to eIF-2α and the translational 
machinery, but also to various factors such as STAT IRF1, 
p53, JNK, and p38, as well as engages the NF-kB pathway 
(1, 2, 26). In non-stressed cells, PKR is in a monomeric 
latent state due to the autoinhibitory effect of its dsRBD, 
which occludes the KD and regulates the activation of the 
kinase. The different dsRNA molecules are recognised and 
bound by PKR through the two N-terminal dsRBM, 
resulting in PKR activation and autophosphorylation (27). 
The structure of the PKR dsRNA binding domain was 
determined by nuclear magnetic resonance (28) offering a 
satisfactory explanation for the length required of dsRNA 
molecules to be effective PKR activators. Most natural 
dsRNA activators of PKR are synthesised in virus-infected 
cells as by-products of viral replication or transcription. 
For RNA viruses, dsRNA replicative forms are obligatory 
intermediates for the synthesis of new genomic RNA 
copies. Complex DNA viruses such as vaccinia virus 
(VV), adenovirus, or herpes simplex virus (HSV) have 
open reading frames in opposite orientation; they produce 
overlapping mRNA transcripts that can fold to form 
dsRNA stretches responsible for PKR activation in 
infected cells (1, 2). After binding dsRNA, PKR undergoes 
a number of conformational changes that relieve the 
autoinhibitory interactions of the enzyme and allow 
subsequent substrate recognition. Biochemical and genetic 
data have underscored the importance of 
homodimerisation in PKR activation (29). After 
homodimerisation, PKR undergoes rapid 
autophosphorylation in a stretch of amino acids termed the 
activation segment. Among others, residues Thr446 and 
Thr451 in this segment are consistently phosphorylated 
during activation (29, 30). This further stabilises PKR 
dimerisation, which in turn increases the catalytic activity 
of the kinase. Whether of viral origin or pIC, dsRNA thus 
not only induces effects on translation, but also influences 
various signal transduction pathways that affect different 
transcriptional activities. As such, PKR mediates the 
dsRNA-induced transcription of many genes through 
engagement of multiple transcription pathways (1, 2, 26).  
2.2. Translation regulation by PKR 
A number of reports have provided insights into the 
mechanism of PKR activation and eIF2α phosphorylation, 
which consists of a three-step pathway in which 
dimerisation of the kinase domain triggers 
autophosphorylation, in turn promoting specific 
recognition of eIF2α. PKR activation-segment 
phosphorylation on Thr446 promotes substrate recognition 
and phosphorylation, although it has been reported that 
phosphorylation at tyrosine residues in PKR also 
contributes to the binding to dsRNA, autophosphorylation, 
and eIF2α phosphorylation (31). To this day, a total of 14 
phosphorylation sites have been identified in PKR, but 
only 12 are biochemically verified, and 8 have been 
functionally characterised (32). Although phosphorylation 
of most sites serves to augment kinase activity toward 
eIF2α, only phosphorylation of T451 is required to 
generate an active kinase (32). As predicted for a 
translation regulator, PKR is associated to ribosomes, 
mainly to 40S subunits (33). Ribosomal association of 
PKR appears to be mediated by the dsRBD, strengthening 
the role of these domains in the correct regulation of PKR 
activity. PKR localisation in ribosomes offers a 
satisfactory explanation for its local activation in response 
to limited stimulus, as reported by several studies (1, 2, 
33). Two models have recently suggested new evidence 
for a sentinel model of ribotoxin-induced PKR activation 
(34). One possibility is a sentinel model in which PKR 
monomers basally associate with the ribosome and rRNA. 
Upon interaction with a ribotoxin, one or more portions of 
rRNA reposition and thereby promote dimerisation of the 
PKR monomers followed by autophosphorylation and self-
activation. A second possibility is a sequential mode 
whereby a ribotoxin first associates with rRNA and inflicts 
damage and/or alters its structure, thereby exposing new 
double-stranded (ds)rRNA regions. This could sequentially 
elicit the binding of two or more PKR monomers in close 
proximity to the damaged site, followed by the 
dimerisation of these monomers and finally the 
autophosphorylation and self-activation of the kinase (34). 
2.3. NF-κB activation by PKR: identification of TRAF 
family proteins linking PKR with NF-κB activation 
The NF-κB family of transcription factors controls the 
expression of genes involved in immune and inflammatory 
responses, cell differentiation, and apoptosis, among others 
(35). NF-κB activation is primarily regulated through its 
interaction with the family of inhibitory proteins IκB 
which retain NF-κB in the cytoplasm. Phosphorylation of 
IκB on two conserved serine residues is mediated by the 
IκB kinase complex (IKK complex) in response to a 
variety of stimuli, leading to its subsequent ubiquitin-
dependent degradation by the 26S proteasome. This allows 
NF-κB translocation to the nucleus, where it can activate 
the transcription of a number of genes including those 
encoding cytokines, chemokines, cell surface receptors, 
and adhesion molecules (36). The IKK complex contains a 
structural protein termed IKKγ or NEMO and two kinase 
subunits, IKKα and IKKβ (37). The first clues suggesting a 
role for PKR in NF-κB activation arose from observations 
in 1989 that dsRNA could induce NF-κB activity in 
different cell lines (38). Subsequent experiments using the 
kinase inhibitor 2-aminopurine suggested a role for PKR in 
this process. Additional evidence came from the analysis 
of NF-κB activation following dsRNA treatment in cells 
lacking PKR expression. When PKR expression was 
downregulated using 2-5A antisense oligonucleotides, 
diminished NF-κB activation was observed in response to 
dsRNA, with no significant change in the response to 
TNF-α (39). The design of mice deficient in PKR 
expression in 1995 allowed carry out many critical 
experiments for studying the mechanism of action of the 
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kinase (40). In fact, experiments performed with PKR-/- 
MEF showed that NF-κB activation was impaired in 
response to pIC treatment. As a consequence of the NF-κB 
activation impairment, PKR-/-  MEF show defects in IFN 
production compared with wt MEF (40). The first 
experiments to show the ability of PKR to activate NF-κB 
in the context of viral infection came from the laboratory 
of Dr Esteban in 1999-2000. These experiments were 
performed with human cells and vaccinia virus 
recombinants expressing PKR in an inducible manner 
(Figure 1), showing that IκBα phosphorylation on serines 
32 and 36 precedes its degradation and translocation of 
NF-κB to the nucleus (41, 42). 
 
 
Figure 1. Scheme of the recombinant vaccinia virus vectors. The Western Reserve strain of vaccinia virus was used to generate 
recombinant viruses expressing the human wild type (WT) and the mutant PKR proteins. The recombinant genes were inserted in the TK 
locus of viral genome. PKR expression is regulated by the lac I repressor gene that is under the control of VV early-late promoter p7.5. 
The mutant PKR, K296R has lost the catalityc activity of PKR due to substitution of the lysine 296 by arginine. These vectors allow over-
express proteins in culture cell lines under IPTG (isopropil-β-D-1-tiogalactopiranósido) induction. Most of our interest genes were over-
expressed using these recombinant vectors. 
Initial reports indicated that PKR was the protein 
kinase that phosphorylated IκBα directly in response to 
dsRNA, based on in vivo and in vitro evidence (43). 
Although PKR appears to be necessary for transducing this 
signal (1, 2, 43, 44), later evidence pointed to an indirect 
role for PKR in IκB phosphorylation. Mutant cells lacking 
IKKγ were unable to induce NF-κB in response to pIC 
treatment (45). Although the kinase NIK was initially 
proposed to be downstream of PKR in the IKK activation 
process, the participation of NIK in this pathway seems 
dubious by virtue of current knowledge of IKK signalling 
(1, 2, 37). Although the evidence is consistent with PKR 
playing a role in the activation of IKK in response to 
dsRNA, the nature of such role is still unclear. In fact, 
research groups have disagreed on whether the catalytic 
activity of PKR was necessary or not for the successful 
activation of NF-kB. In this regard, the studies led by Dr 
Esteban’s group made significant contributions and 
provided some interesting experiments demonstrating the 
essential action of the catalytic domain of PKR. In this 
exciting and pioneering environment is where I began my 
research of the mechanism of action of PKR as a PhD 
student under the direction of Dr Esteban. Our experiments 
showed that the association with the IKK complex seems 
to involve the PKR catalytic domain, as mutational 
analysis suggested (46). Experiments using PKR-/- cells 
suggested that PKR catalytic activity is needed for IKK 
activation using vaccinia virus recombinants expressing 
several PKR mutants (Figure 1), (46). Similar results were 
found by Dr Williams’s group, in a study in which the 
complementation of PKR-/- MEF with plasmid expressing 
wt PKR (but not with a catalytically inactive mutant) 
restored appropriate NF-κB and IRF-1 activation (44). 
However, experiments from other groups carried out on 
NIH 3T3 cells suggested that a catalytically inactive PKR 
mutant is a poor IKK activator, but when PKR is 
expressed at high levels it can activate IKK efficiently 
(47). Purified PKR, either wt or mutant K296R, activated 
the recombinant IKK protein, suggesting that PKR 
catalytic activity was not needed in the process (48, 49). It 
has been suggested that the variety of models used in the 
different groups can yield either result, also accepting that 
the catalytic activity of PKR may or may not be necessary 
to activate NF-κB depending on the type of stimulus 
triggering the process, and the cellular stress stage. 
A major part of my doctoral thesis looked into ways to 
decipher the mechanism by which PKR activates NF-κB 
transcription factor. Sharing first authorship with Dr Gil, in 
2004 we published an original article in Molecular and 
Cellular Biology about how TRAF family proteins link 
PKR with NF-κB activation. Since then, this piece of 
research has been cited over 80 times. Several pathway-
specific adapter proteins, such as members of the TRAF 
(TNF receptor associated factors) family, MyD88, TIRAP, 
and TRIF, act as mediators that link different pathways 
with IKK activation (1, 2, 50). TRAF proteins have 
emerged as key signal transducers not only downstream of 
TNF receptors, but also in other pathways (50). We 
identified two putative TRAF-interacting motifs in the 
PKR sequence, and the viability of the PKR/ TRAF 
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interaction was suggested by bioinformatic analysis and 
confirmed in vivo (51). The interaction between PKR and 
TRAF2 or TRAF5 was shown to be dependent on PKR 
dimerisation and is functionally relevant, as we 
demonstrated in cells genetically deficient in TRAF2 and 
TRAF5 or after expression of TRAF dominant negative 
molecules, suggesting that TRAF family proteins act 
downstream of PKR and signal towards the activation of 
NF-κB (51). With our study as a starting point, other 
groups have linked PKR/TRAF with several signalling 
pathways with significant relevance in the induction and 
activation of Interferon type I, such as TLR-related 
pathways (52). Recently PKR/TRAFs have been also 
involved in the protection against a disease caused by a 
non-viral pathogen (53). 
3.4. PKR involvement in different signalling pathways: 
New PKR networks through microarray analysis 
The number of functions that PKR plays is in 
correlation with its participation in numerous signalling 
pathways that have been described over several studies (1, 
2, 26) (Figure 2). 
 
Figure 2. PKR is a cellular sensor implicated in the detection of viral RNA and subsequent interferon gene expression. Viral RNA 
sensors as retinoic acid-inducible gene I (RIG-I) and melanoma differentiation associated gene 5 (MDA5), and the membrane sensors as 
the Tool-like receptors TLRs were discovered after PKR, adding complexity to viral host recognition. PKR is an intermediary component 
in TLR signalling. PKR is implicated in the LPS/TLR4-mediated pathway probably recruited by the TIRAP complex. PKR is also 
involved during the dsRNA/TLR3 pathway, recruited by a TAK1-containing complex. Moreover, PKR is crucial for the IFN- α/β 
production in response to MDA5-dependent viruses. In addition PKR link RIG-I in the antiviral stress granules function and formation. 
PKR was one of the first cellular sensors implicated in 
the detection of viral RNA and subsequent interferon 
(IFN) gene expression. However, this clear picture of PKR 
antiviral function was complicated by the discovery of 
cytosolic viral RNA sensors such as retinoic acid-inducible 
gene I (RIG-I) and melanoma differentiation-associated 
gene 5 (MDA5), and membrane sensors as the toll-like 
receptors TLRs (Figure 2), (54). Since then, the role of 
PKR as RNA sensor was minimised, and the focus moved 
to the role of other sensors. However, it has been 
demonstrated that PKR plays an essential role in IFN-α/β 
production in response to viral infections by regulating the 
integrity of IFN-β transcripts. By using PKR-deficient 
cells, it has been possible to show that PKR is crucial for 
IFN- α/β production in response to MDA5-dependent 
viruses like encephalomyocarditis virus (EMCV), 
Theiler’s murine encephalomyelitis virus (TMEV) and 
Semliki Forest virus (SFV), but not to RIG-I-dependent 
viruses such as Sendai virus or influenza (55). However, it 
has been suggested recently a new link between PKR and 
RIG-I in the antiviral stress granules function and 
formation (56, 57).  In addition, the idea of PKR as key 
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regulator of IFN protein synthesis has been also supported 
by other studies demonstrating that PKR plays a non-
redundant role in the IFN response to viral infections (54).  
On the other hand, it is well-known that PKR is a 
potent activator of NF-kB, thereby inducing IFN 
transcription in concerted action with interferon regulatory 
factors 3 and 7 (IRF-3/7). PKR has been also implicated in 
the activation of interferon regulatory factor 1 (IRF 1), 
whose expression is strongly upregulated upon viral 
infection, and which acts mainly as a transcriptional 
activator of IFN-α/ β gene expression (5, 44, 54). PKR also 
controls IFN and dsRNA signalling pathways by 
modulation of STAT1 and STAT3 transcription factors. 
PKR-knockout cells are defective in STAT1 
phosphorylation on Ser727, resulting in a 4-fold decrease 
in STAT1 dependent transactivation (58). STAT1 is also a 
target for PKR-mediated activation in response to 
lipopolysaccharide (LPS) in glial cells (59). PKR also 
associates to STAT3, and is required for full STAT3 
activation in response to platelet-derived growth factor 
(PDGF). As proposed for STAT1, PKR regulates the Erk 
activation ultimately involved in STAT3 phosphorylation 
(60). On the other hand, since it also regulates STATs 
transcription factors, PKR has recently been described to 
be involved in the differentiation of chondrocytes through 
the modulation of STAT1 and Sox-9 expression (61). 
In addition to its well-established role in the interferon 
response, PKR is involved in many cellular pathways 
exerting various functions on cell growth and 
tumourigenesis (1, 2, 26). For example, the link between 
PKR and p53 has been described fundamentally in cancer 
cells where there is a bidirectional and complex regulatory 
relationship between both proteins. PKR interacts directly 
with the C-terminal part of p53 and phosphorylates p53 at 
the Ser392 residue (62). In addition, PKR is able to 
promote the proteasomal degradation of p53 in association 
with GSK-3β and mouse double minute 2 homologue 
(Mdm2), independently of translational control (57). 
Moreover, it has been demonstrated that the ability of p53 
to cause cell cycle arrest and regulate transcription of 
target genes was impaired in PKR-knockout cells (62). In 
fact, it has been suggested that PKR is a p53 target gene 
that plays an important role in the tumour-suppressing 
function of p53 (63).  
Moreover, PKR is an activator for signalling cascades 
involving stress-activated protein kinases, and is described 
to mediate Jun kinase (JNK) and mitogen-activated protein 
kinase p38 (MAPK) activation in response to specific 
stimuli (1, 26). For full activation in response to LPS or 
cytokines such as IFN-γ, interleukin (IL)-1, or tumour 
necrosis factor (TNF)-α, both p38 and JNK are dependent 
on PKR (64). Moreover, PKR interacts with and activates 
mitogen-activated protein kinase kinase 6 (MKK6) in 
response to double-stranded RNA stimulation (65). 
In order to improve the state of knowledge about new 
host genes affected by PKR, we used human cDNA 
microarrays to identify, in infected cells, genes 
differentially expressed after PKR expression, and 
analysed the requirements of catalytic activity of the 
enzyme (66). To express PKR, we used vaccinia virus 
recombinants producing wild type PKR and the 
catalytically inactive mutant K296R (Figure 1). Most 
regulated genes were classified according to biological 
function, including apoptosis, stress, defence, and immune 
response. A total of 111 genes were regulated specifically 
by PKR catalytic activity, highlighting the upregulation of 
the ATF-3 transcription factor, involved in stress-induced 
β-cell apoptosis. Using null cells for ATF-3 and for the 
p65 subunit of NF-κB, we showed that induction of 
apoptosis by PKR at late times of infection was dependent 
on ATF-3 expression and regulated by NF-κB activation. 
The host genes affected by PKR, identified using human 
cDNA microarrays, together the ATF3 implication were 
published by Dr Guerra and co-workers in 2005 under the 
direction of Dr Esteban in the Journal of Biological 
Chemistry (66). 
2.5. PKR is a potent pro-apoptotic protein: caspases 
activation by intrinsic and extrinsic routes    
Cell death by apoptosis is a genetic program of 
multicellular organisms which implements the ordered 
removal of damaged or unwanted cells during 
development and in adult life. Deregulation of the 
apoptotic process can lead to pathological conditions such 
as cancer, autoimmunity, and neurodegeneration (67). 
Induction of apoptosis is a common response to viral 
infection. Although it may represent an antiviral 
mechanism that acts by rapidly eliminating infected cells 
and preventing viral spread, virus-induced apoptosis can 
also have important pathological implications. Moreover, 
apoptosis cell death is an important event during some 
chemotherapy treatments in cancer diseases. 
The first evidence that PKR was involved in apoptosis 
was suggested by Dr Esteban’s group in 1994 using HeLa 
cells infected with a VV recombinant vector that expressed 
the enzyme under inducible conditions (Figure 1), (68). 
The role of PKR in apoptosis was reinforced by studies 
developed by other groups with 3T3 cells expressing a 
noncatalytic mutant PKR or using MEF derived from 
PKR-/- mice (69, 70). Since then, it has been clearly 
demonstrated that PKR mediates the apoptosis induced by 
several viruses such us poxviruses, influenza, EMCV, 
VSV, etc., probably through dsRNA production (1, 2). 
PKR also regulates apoptosis induced in the absence of 
viral infection. PKR was shown to mediate the apoptosis 
observed during Alzheimer's disease (71) and induced by 
oncogenes such as IRF1 or E2F-1, or triggered in response 
to dsRNA, TNFα, LPS, tunicamycin, serum starvation, or 
IL-3 withdrawal (1, 2). Many of the stimuli that trigger 
PKR-dependent apoptosis in the absence of viral infection 
rely on PACT/RAX activation. PACT/RAX mediates PKR 
activation and subsequent apoptosis in response not only to 
cytokines and serum withdrawal, but also to 
chemotherapy, ethanol, and viral infection (23, 24, 72). 
Analysis of the role of PKR effectors in mediating cell 
death suggests an intricate pathway. To distinct degrees, at 
least eIF-2α, NF-kB, ATF-3, and p53 have been implicated 
A historical overview of protein kinase PKR… 
@Real Academia Nacional de Farmacia. Spain 149 
in mediating PKR-induced apoptosis (1, 2, 26). Our 
research has provided interesting results involving all these 
factors. Initial evidence that PKR phosphorylation of eIF-
2α is involved in apoptosis induction came from studies 
showing that PKR-mediated apoptosis can be inhibited by 
expressing an eIF-2α dominant-negative mutant (73). 
Using the VV expression system (Figure 1), the group of 
Dr Esteban showed that apoptosis induced by PKR 
expression was prevented by coexpression of an eIF-2α 
51A mutant (73). Moreover, they described the 
involvement of NF-κB activation in the apoptosis induced 
by PKR using proteasome inhibitors that block IκBα 
degradation, or by coexpressing dominant negative forms 
of IκBα. These observations may appear paradoxical, as 
NF-κB is often classified as a prosurvival factor that 
prevents apoptosis. However, there is considerable 
evidence for the context of NF-κB as a pro- or 
antiapoptotic factor, depending on the stimulus that 
triggers the apoptosis (1, 2, 41, 42). Subsequently, we 
contributed to the discovery of a new transcription factor 
involved in the apoptosis induced by PKR (66). The ATF-
3 transcription factor, involved in stress-induced β-cell 
apoptosis, was upregulated after PKR over-expression. 
Activation of endogenous PKR with a VV mutant lacking 
the viral protein E3L, a PKR inhibitor, triggered an 
increase in ATF-3 expression that was not observed in 
PKR-knockout cells. Using null cells for ATF-3 and for 
the p65 subunit of NF-κB, we showed that induction of 
apoptosis by PKR at late stages of infection was dependent 
on ATF-3 expression and regulated by NF-κB activation 
(66). Other potential mediators of PKR-induced apoptosis 
are the components of the Arf/p53 pathway. The p53 
pathway is a critical regulator of apoptosis (1, 2), and the 
link between PKR and this pathway has been established 
at several levels. Our recently published work in the field 
is discussed below. IRF-1 is another PKR target involved 
in apoptosis induction (44). 
To understand how the activation of PKR effectors 
regulates apoptosis induction, it is necessary to understand 
how the apoptotic machinery integrates these signals. 
Proteolytic enzymes such as caspases are important 
effector molecules in apoptosis. Caspases are synthesised 
as inactive proforms and, upon activation, they cleave next 
to aspartate residues. Activation of caspases can be 
initiated from different entry points, as for example at the 
plasma membrane upon ligation of death receptor 
(receptor pathway/extrinsic pathway) or at the 
mitochondria (mitochondrial pathway/intrinsic pathway) 
level. Stimulation of death receptors of the tumour 
necrosis factor (TNF) receptor superfamily, such as CD95 
(APO-1/Fas) or TNF-related apoptosis-inducing ligand 
(TRAIL) receptors, results in activation of the initiator 
caspase-8, which can propagate the apoptosis signal by 
direct cleavage of downstream effector caspases such as 
caspase-3. The mitochondrial pathway is initiated by the 
release of apoptogenic factors such as cytochrome c, 
among others, from the mitochondrial intermembrane 
space. The release of cytochrome c into the cytosol 
triggers caspase-3 activation through formation of the 
cytochrome c/Apaf-1/caspase-9-containing apoptosome 
complex. Links between the receptor and the 
mitochondrial pathway exist at different levels. Upon 
death receptor triggering, activation of caspase-8 may 
result in cleavage of Bid and Bax, Bcl-2 family proteins 
which in turn translocate to mitochondria to release 
cytochrome c, thereby initiating a mitochondrial 
amplification loop. Finally, activation of caspase-3 triggers 
the induction of cell death by apoptosis (1, 74), (Figure 3). 
Our research on the mechanism of action involved in 
apoptosis induced by PKR has been very active. The group 
led by Dr Esteban showed that PKR-induced apoptosis 
involves mainly the FADD/caspase 8 pathway. Expression 
of a FADD dominant-negative mutant or MC159L (from 
molluscum contagiosum virus, MCV) by using VV 
recombinants blocked PKR-induced apoptosis and 
decreased caspase 8 activity, showing that PKR triggers 
apoptosis through FADDmediated activation of caspase 8 
(75). In 2002, we found that PKR expression by VV 
recombinants also induces caspase 9 activation, which 
correlates with Bax protein translocation to the 
mitochondria and cytochrome c release to the cytoplasm, 
resulting in mitochondrion depolarisation (76). The PKR-
induced caspase 9 biochemical process occurred 
downstream of caspase 8 activation, as treating cells with 
an inhibitor of caspase 9 results in partial prevention of 
PKR-induced apoptosis (76). Also a part of my doctoral 
thesis, this work showed both the extrinsic and intrinsic 
pathways that PKR induces during apoptosis (Figure 3). 
María Ángel García Chaves 
@Real Academia Nacional de Farmacia. Spain 150 
 
Figure 3. PKR induces apoptosis activating both, the extrinsic and the intrinsic routes of caspases activation. Through interaction 
with FADD, PKR activates caspase-8, which in turn activates the conversion of Procaspase-3 and provokes Bid/Bax interaction, release 
of cytochrome c from the mitochondria and formation of the apoptosome (Apaf-1/cytochrome c/caspase-9). Both pathways result in 
activation of caspase-3 and degradation of DNA, thus resulting in programmed cell death or apoptosis. 
3. PKR REGULATION 
The importance of PKR function in antiviral defence, 
cell growth, differentiation, stress response, and immune 
modulation is further highlighted by the existence of 
specific direct and indirect modulators. 
3.1. Viral modulators of PKR effect: E3L from vaccinia 
virus, LANA 2 from Kaposi’s sarcoma herpesvirus, and 
polyprotein from hepatitis c virus as subjects of our 
interest 
Since the IFN-induced cellular antiviral response is the 
primary defence mechanism against virus infections, many 
viruses have developed a means to counteract the 
induction or effects of IFN (1, 2). Viruses use a number of 
strategies to counteract dsRNA-dependent pathways, and 
specifically to avoid the deleterious effects of the PKR and 
other IFN-induced systems. Numerous viral proteins have 
been identified as able to avoid the PKR effect, directly 
binding PKR or indirectly preventing eIF2α 
phosphorylation. One recently-researched mechanism that 
contributes indirectly by inhibiting the effect of PKR is 
mediated by growth arrest and DNA damage-inducible 
protein 34 (GADD34), which physically interacts with 
phosphatase-1 cofactor PP1c leading to enhanced 
dephosphorylation of eIF-2α (77). In addition, some viral 
mRNA could initiate translation in an eIF2-independent 
manner by means of a dedicated RNA structure that stalls 
the scanning 40S ribosome on the initiation codon (78). 
Viral inhibitors are normally expressed from the onset of 
infection to maintain PKR inactive until the virus cycle is 
completed. Elimination of PKR inhibitors from these 
viruses generally has a severe impact on virus replication 
and pathogenesis. Viruses disarmed of PKR inhibitors 
usually replicate at lower levels than wild-type viruses in 
normal cultured cells, and show an attenuated phenotype 
in animals. A detailed analysis of different viral proteins 
inhibiting PKR was made in our reviews in 2006 (1, 2). In 
the present review, an update with new viral proteins is 
displayed in Table 1. In addition, our contribution to the 
study of different viral proteins modulating the PKR effect 
is also discussed.  
Vaccinia virus (VV) and its derivative viruses have 
been widely used by the group of Dr Esteban, and are still 
being researched as very promising vaccines against 
several infections and diseases (HIV, HCV, malaria, 
cancer, etc.) (79). VV is relatively resistant to the antiviral 
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effects of IFN and is able to rescue the replication of IFN-
sensitive viruses such as VSV and EMCV following co-
infection. Earlier findings suggested that VV resistance to 
IFN was related to interference between the virus and the 
IFN system (80). Later studies showed a more complex 
landscape, with the VV genome encoding secreted proteins 
that bind to receptors and ligands of cytokines and 
chemokines (1, 2, 81), and at least two proteins, K3L and 
E3L, with the ability to inhibit intracellular IFN-induced 
pathways. More recently, another protein (K1) has been 
identified as a possible PKR inhibitor (82). The K3L 
protein is expressed early in VV infection. K3L protein 
binds directly to PKR in vitro, and yeast two-hybrid 
interaction assays have localised the K3L protein-binding 
site to the C-terminal half of the PKR kinase domain. 
Competition binding experiments and sequence homology 
between K3L and the N-terminal one-third of eIF-2α (72% 
similarity and 28% identity) suggest that PKR recognises 
K3L and eIF-2α by a common mechanism (1, 2). In this 
way, K3L protein inhibits autophosphorylation of PKR, 
blocking the subsequent inhibition of protein synthesis (1, 
2, 83). The role of the E3L gene as an inhibitor of 
apoptosis was first detected after infection of HeLa cells 
with an E3L deletion mutant of VV by Dr Esteban´s group 
(1, 68). The VV E3L gene encodes two proteins, p25 and 
p20, expressed early in infection. E3L is a host range gene, 
necessary for efficient VV replication in several cell lines, 
and is required for VV pathogenesis. The E3L protein is a 
dsRNA-binding protein where the carboxy-terminal 
domain of E3L encodes the conserved motif that binds 
dsRNA. The N-terminal domain required for 
neurovirulence is involved in the direct inhibition of PKR 
activation, nuclear localisation, and Z-DNA binding (1, 2, 
84). E3L also inhibits PKR by direct interaction with PKR, 
leading to heterodimer formation (1, 85). Our contribution 
in the study of E3L protein showed that E3L expression in 
NIH 3T3 cells conferred antiapoptotic and oncogenic 
properties. To analyse E3L effects over cellular 
metabolism in a virus-free system, we generated stable 
mouse 3T3 cell lines expressing E3L (86). Expression of 
E3L resulted in inhibition of eIF-2α phosphorylation and 
IkBα degradation in response to dsRNA. Antiviral 
responses induced by IFN-α/β were partially impaired in 
3T3-E3L cells, as we determined by a viability assay upon 
VSV infection. E3L expression also conferred resistance to 
dsRNA-triggered apoptosis. Interestingly, cells expressing 
E3L grew faster than control cells, and showed increased 
expression of cyclin A and decreased levels of p27Kip1. 
E3L cooperated with H-ras in a focus formation assay, and 
NIH3T3 E3L cells formed solid tumours when injected in 
nude mice. Overall, our findings reveal that interference of 
E3L protein with several cellular pathways results in 
promotion of cellular growth, impairment of antiviral 
activity, and resistance to apoptosis (86). These results 
(which we published with my contribution as the first 
author in Oncogen journal in 2002) together with the 
previously described works, led me to writing my doctoral 
thesis “Mechanism of action and regulation of Protein 
Kinase induced by Interferon: PKR/ Mecanismo de acción 
y regulación de la Proteina Quinasa inducida por 
Interferón:PKR”, which received the Special Award 
(Premio Extraordinario) of the Autonomous University of 
Madrid.  
Recently, in collaboration with the group of Dr Rivas, 
we have described the regulation of the E3L protein by 
small ubiquitin-like modifier proteins. E3L interacts with 
SUMO1 through a small ubiquitin-like modifier (SUMO)-
interacting motif (SIM). SIM integrity is required for 
maintaining the stability of the viral protein and for the 
covalent conjugation of E3 to SUMO1 or SUMO2, a 
modification that has a negative effect on the E3L 
transcriptional transactivation of several apoptotic genes 
(87). My collaboration with Dr Rivas started in 2003, and 
since then we have made several significant contributions 
to the knowledge about the link between tumour 
suppressors and antiviral activity, resulting in some of the 
works described in the present review. 
Kaposi's sarcoma herpesvirus (KSHV). In 
collaboration with Dr Rivas, we showed that the viral 
protein LANA2 codified by KSHV inhibits apoptosis and 
the PKR-mediated translational block (88), and we 
identified a nuclear export signal with important 
implications for the function of this viral protein (89). 
Hepatitis C virus (HCV). We looked deeper into the 
mechanisms of action of other viral proteins modulating 
PKR and, in order to analyse the effects of hepatitis C 
virus (HCV) on the antiviral response of the host, we 
developed a novel vaccinia virus (VV)-based delivery 
system polyprotein expression (VT7-HCV7.9), where 
structural and nonstructural (except part of NS5B) proteins 
of HCV ORF from genotype 1b were efficiently expressed 
and produced, and timely regulated in mammalian cell 
lines. HCV polyprotein expression caused a severe 
cytopathological effect in human cells as a result of the 
inhibition of protein synthesis and apoptosis induction 
triggered by the activation of the IFN-induced enzymes 
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Table 1: Viral inhibitors of PKR effect 
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3.2. PKR modulation by cellular components  
Other functions of PKR (apart from its antiviral 
activity) have surfaced with the discovery of numerous 
proteins and other cellular structures modulating the 
kinase. Moreover, some cellular proteins also modulate 
PKR to regulate the antiviral and immunomodulatory 
responses. 
p58IPK. A member of the tetratricopeptide repeat 
family, p58IPK is was the first reported cellular inhibitor 
of PKR (110). p58IPK interacts directly with PKR and 
inhibits its kinase activity by preventing dimerisation. 
Influenza virus partially evades the host's antiviral 
response by recruiting p58IPK to repress PKR-mediated 
eIF-2α phosphorylation (1, 2, 111). In the absence of viral 
infection, p58IPK overexpression results in malignant 
transformation. Although the exact mechanism has not 
been defined, it has been suggested that p58IPK 
transforms cells by interfering with PKR-regulated 
pathways. PKR inhibition by p58IPK can stimulate cell 
growth by disrupting PKR-dependent control of mRNA 
translation and by blocking PKR-dependent apoptosis (1, 
112). Interestingly, an independent antiviral link has 
recently been identified between both proteins, PKR and 
p58IPK, involving joint degeneration in mice (113). 
PACT. The first protein described as PKR activator 
was PACT (PKR activating protein) able to activate PKR 
in response to several stresses (1, 23, 24, 72). PACT is a 
ubiquitously expressed protein that belongs to the family 
of dsRNA-binding proteins and has three dsRNA-binding 
domains. Although most studies show that PACT is 
necessary for PKR activation in response to different toxic 
compounds, such as arsenic, H2O2, and tunicamycin, 
PACT-knockout cells and mice did not exhibit significant 
differences in the response to stressful stimuli compared to 
a wild-type phenotype (114). Recently, a possible role of 
PACT as an inhibitor of PKR during HIV-1 replication has 
been described (115).  
TRBP. Trans-activation response RNA-binding protein 
(TRBP) is a potent PKR modulator that, in turn, regulates 
PACT protein. TRPB has generated great interest because 
of its role in RNA interference and microRNA (miRNA) 
processing (116). Since TRBP inhibits PACT and PKR 
activation, both modulators are under intensive analysis as 
potential therapeutic targets. TRBP is a cellular RNA-
binding protein isolated by its ability to bind human 
immunodeficiency virus type 1 (HIV-1) TAR RNA (117, 
118). Proposed TRBP functions include inhibition of PKR 
activation, regulation of cell proliferation, PKR-
independent translational activation, modulation of HIV-1 
gene expression through its association with TAR, and the 
control of mRNA translation. TRBP and PKR form a 
complex using direct protein-protein interaction through 
their dsRBDs that prevents PKR activation (116). 
Chaperones. Chaperones are PKR modulators that 
have a spectrum of inhibitors currently being tested in 
preclinical studies with promising expectations (119). PKR 
is negatively regulated by the heat-shock protein 90 
(Hsp90). The drug geldanamycin, an inhibitor of Hsp90, 
disrupts the interaction of the PKR-Hsp90-p23 complex, 
allowing PKR activation (1, 2). It has been suggested that 
Hsp90 contributes to chemotherapy resistance, and its 
inhibition has potential therapeutic interest. Similar to 
Hsp90, Hsp70 binds to PKR, inhibits PKR 
phosphorylation, and prevents apoptosis (120). In stressed 
cells, Hsp70 binds to the Fanconi anemia complementation 
group C (FANCC) protein and forms a ternary complex 
with PKR (1, 2). Consequently, hematopoietic cells with 
FANCC mutations or downregulated Hsp70 show 
constitutive PKR activation and sensitivity to various cell 
stress signals as well as to IFN-based therapy (121). 
Overall, the evaluation of HSPs in cells with different 
basal levels of PKR activation may open an interesting 
field of study on the regulation of PKR and its therapeutic 
modulation. 
NPM. Nucleophosmin (NPM; also known as B23) is 
an abundant and ubiquitously expressed nucleolar 
phosphoprotein implicated in ribosome biogenesis (1, 
122). It binds nucleic acids, has intrinsic RNase activity 
and also acts as a molecular chaperone shuttling between 
the nucleus and cytoplasm. NPM has also been implicated 
in the acute response to environmental stress and controls 
cell proliferation (1, 2). NPM is frequently overexpressed 
in tumours of diverse origin (123), and it is translocated in 
lymphomas and leukemias. NPM interacts with PKR, 
inhibiting eIF-2α phosphorylation and PKR-mediated 
apoptosis (124). It was suggested that the capacity of NPM 
to inhibit PKR activation could explain how NPM 
promotes cell proliferation and suppresses the apoptosis 
pathway (1). We have identified a novel function for NPM 
involving PKR activity with important antitumour and 
antiviral consequences, as we analyse in the next section.  
3.3. PKR regulation by miRNAs  
The first miRNA identified acting on PKR is the 
noncoding RNA (pre-miR-886) called nc886 (125, 126). 
MiRNAs, small noncoding regulatory factors 18–25 nt in 
length, could affect gene expression leading to 
translational and transcriptional regulation of numerous 
genes and consequently affect protein expression including 
kinases. MiRNAs have crucial roles in diverse biological 
processes, including apoptosis and cell growth. Multiple 
studies have reported altered miRNA levels in stressed 
cells or in various disease states, including cancer and 
neurodegenerative pathologies. Because of its stability and 
easy detection in body fluids, they are being explored as 
important biomarkers in various diseases. The extent of 
miRNA involvement in PKR regulation and activity is still 
not fully understood, but studies have begun to identify 
miRNA-mRNA targets of kinases involved in different 
pathologies. The pre-microRNA nc886 suppresses PKR 
via direct physical interaction, whereas artificial 
suppression of nc886 in cholangiocyte cells activated the 
canonical PKR/eIF2α cell death pathway (126). The 
importance of the detection of nc886 has been recently 
revealed in two studies with oncologic patients where 
nc886 levels in the tumour were related with the 
progression of the disease (127). Methylation studies 
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conducted in PBMCs from acute myeloid leukemia and 
healthy patients have shown epigenetic variability of 
nc886 (128), suggesting that the expression levels of this 
regulator will be variable, and may be decisive in diseases 
where PKR activity is deregulated. 
3.4. PKR regulation by compartmental localisation and 
post-translational modifications: identification of a novel 
PKR modification by Sumoylation 
Although PKR has been identified in nuclear and 
cytoplasmic fractions, most activities attributed to PKR 
occur in the cytoplasm; hence, the role of nuclear PKR 
remains unclear. However, recent studies have attributed 
clinical and pathological significance to nuclear PKR, 
mainly in neurodegeneratives diseases (21, 129). 
Moreover, we and others have shown that PKR can be 
sequestered in the nucleus by nucleophosmin (1, 2). In 
acute leukemia, it has been found that PKR exists in 
diverse molecular weight forms in the nucleus, suggesting 
that this variance in protein weight is the result of post-
translational modifications (129). In fact, PKR can be 
regulated by different post-translational modifications, 
including phosphorylation, ubiquitination, and ISGylation. 
Recent observations resulting from the cooperation 
between our group and that of Dr Rivas reveal a post-
translational modification of PKR by SUMOylation, with a 
direct role in PKR activation and control of virus infection 
(130). These results indicate that PKR is modified by both 
SUMO1 and SUMO2, in vitro and in vivo. We identified 
lysine residues Lys-60, Lys-150, and Lys-440 as 
SUMOylation sites in PKR. Moreover, these results show 
that SUMO is required for efficient PKR-dsRNA binding, 
PKR dimerisation, and eIF2α phosphorylation. SUMO 
potentiated the inhibition of protein synthesis induced by 
PKR in response to dsRNA, whereas a PKR SUMOylation 
mutant was impaired in its ability to inhibit protein 
synthesis and showed reduced capability to control 
vesicular stomatitis virus replication and to induce 
apoptosis in response to vesicular stomatitis virus infection 
(130). Hence, the analysis of the post-translational 
regulation and compartmentalisation of PKR offer 
interesting possibilities to control their role in various 
diseases. 
4. PKR INVOLVEMENT IN SEVERAL DISEASES: 
ITS POTENTIAL AS A BIOMARKER AND 
THERAPEUTIC TARGET 
The study of the mechanism of action and regulation of 
PKR has opened the door to a new understanding of the 
implications and therapeutic possibilities of this protein in 
several diseases as we have recently published in FASEB 
Journal in the review titled “The impact of PKR 
activation: from neurodegeneration to cancer” under my 
leadership as corresponding and last author (131). 
Although further analysis are required involving patient 
samples, PKR translational research, carried out only in 
recent years, shows great potential for this kinase as a 
biomarker and therapeutic target.  
 My incorporation at the University Hospital 
Complex of Granada as a Researcher of the National 
Health System (Miguel Servet Program) was in 2009, with 
the aim of transferring our knowledge of PKR and 
Interferon to certain diseases, conducting studies with 
patients in order to define their clinical utility. Today, I 
lead a line of research based on the study of Interferon and 
PKR in several diseases at the Institute of Biomedical 
Research of Granada (ibs.GRANADA)/University 
Hospital Complex of Granada, in the group directed by Dr 
Marchal, collaborating also in the discovery of novel 
antitumour drugs. 
4.1. The role of PKR in Cancer 
In addition to its well-established role in the interferon 
response, PKR is involved in many cellular pathways 
exerting various functions on cell growth and 
tumourigenesis (1, 2, 131). However, PKR's exact role in 
cancer biology remains controversial. Initially, PKR was 
thought to be a tumour suppressor. The first evidence that 
PKR controls cell growth, and consequently may function 
as an inhibitor of cell proliferation, was obtained after 
overexpression of PKR in mammalian, insect, and yeast 
cells, where PKR was observed to suppress cell growth 
(132, 133). Conversely, the expression of several PKR 
dominant-negative mutants leads to malignant 
transformation of NIH 3T3 cells, and is able to cause 
tumourigenesis in nude mice (134, 135). The apoptotic 
role of PKR was also in agreement with the notion that this 
protein could be a tumour suppressor. PKR is able to 
activate the intrinsic and extrinsic apoptotic routes in 
cancer cells in response to several stimuli, including 
antitumour drugs (22, 76). Moreover, PKR has been 
suggested as an essential part of the antitumour activity of 
tumour suppressors, such as p53 and PTEN (62, 63, 136). 
The link between PKR and p53 has been described 
fundamentally in cancer cells where there is a bidirectional 
and complex regulatory relationship between both 
proteins. PKR interacts directly with the C-terminal part of 
p53 and phosphorylates p53 at the Ser392 residue (1, 2, 
62). In addition, PKR is able to promote the proteasomal 
degradation of p53 in association with GSK-3βand mouse 
double minute 2 homologue (Mdm2), independently of 
translational control (131). Moreover, it has been 
demonstrated that the ability of p53 to cause cell cycle 
arrest and regulate transcription of target genes was 
impaired in PKR-knockout cells (1, 2). In fact, it has been 
suggested that PKR is a p53 target gene that plays an 
important role in the tumour-suppressor function of p53 in 
response to DNA damage stress. In addition, PKR could 
be transcriptionally regulated by p53 activity in response 
to some genotoxic stresses (63). On the other hand, we 
have evaluated the antitumour activity of overexpressed 
PKR using VV recombinant (Figure 1) with interesting 
oncolytic results in mice xenotransplanted with prostate 
cancer cells, publishing these data as first author in 2010 in 
Anales de la Real Academia Nacional de Farmacia (137). 
PKR overexppresion was able to reduce tumour volume 
with the advantage of minimising the specific antibodies 
induced by the animal against the viral vector in 
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comparison with the control empty vector, suggesting the 
potential of VV-PKR construction as an oncolytic vector 
for cancer (137). A possible mechanism of evasion of PKR 
activation has been suggested by some cancer cells that are 
unable to induce apoptosis despite eIF2α phosphorylation 
status (131). Moreover, it has been reported that PKR is 
suppressed or inactivated in some malignancies, and 
increased PKR expression has been shown to correlate 
with better prognosis in head and neck cancer, melanoma, 
lung, and colon cancer (1, 131, 138, 139). Furthermore, 
some evidence shows that PKR may act as a tumour 
suppressor in leukemia and could play an important role in 
haematological disorders (129, 131). Other evidence 
supporting the antitumour role of PKR comes from studies 
demonstrating the importance of PKR/eIF2α status in 
cancer response to chemotherapy. Chemotherapeutic drugs 
such as 5-Fluorouracil, doxorubicin and etoposide are able 
to induce and activate PKR protein, triggering apoptosis 
(22, 63, 131, 140).  
However, evidence also suggests an antagonist role of 
PKR in cancer that has challenged the proposed function 
of PKR as a tumour suppressor. It is now well established 
that activation of PKR leads to the induction of pro-
survival as well as pro-death pathways whose balance 
depends on the intensity and nature of the activating 
stimulus as well as the activation or level of expression of 
the PKR´s modulators (Figure 4). 
 
Figure 4. PKR plays an antagonist role in cancer. PKR activation can induce both pro-survival and pro-death pathways. The nature 
and the intensity of activation stimuli as well as the level of expression of PKR´s modulators could decant the balance of consequences of 
PKR activation. Understanding the cellular factors and signals that regulate PKR in the different diseases would be extremely valuable 
from a clinical point of view. 
In fact, it has been reported that PKR was 
overexpressed and linked with malignancy in thyroid 
carcinoma, broncheoalveolar carcinoma, colon, melanoma, 
lung, breast, liver cancers and some haematological 
disorders (131, 141, 142). Moreover, PKR involvement 
has been suggested in the neoplastic process of the 
proliferative transcription factor NF-kB (143). Curiously, 
the finding of different expression patterns of 
PKR/eIF2α/NF-kB activity, even in the same type of 
cancer, points to the complexity of the role of PKR in 
cancer (126). It is important to note that some clinical 
studies related to PKR analysis did not follow a 
standardised protocol, differing in the number of tumour 
samples analysed and in the inclusion criteria of patients, 
which makes it difficult to compare results between 
groups. This fact, together with the complexity of PKR 
signalling and its regulation, highlights the need for 
consensus on a standardised protocol, specifying patient 
inclusion criteria, the appropriate number of samples, and 
the methodology employed. 
4.1.a. PKR involvement in the antiviral activity of several 
tumour suppressors: p53, Arf, and Rb 
An increasing number of tumour suppressor genes are 
induced by interferons and may play an important role in 
the control of cell proliferation induced by this cytokine. In 
addition, pathways triggered by both tumour suppressors 
and IFN converge as common targets for non-related 
tumour viruses. The inhibition of the IFN response by 
animal viruses is explained by the fundamental role that 
IFN plays to control virus infection. However, the reasons 
why many viruses, including those that do not require the 
replication of the host, target tumour suppressor pathways 
are varied and remain under investigation. In fact, 
oncogenic viruses frequently target the pathways 
controlled by tumour suppressor genes, suggesting an extra 
function for these proteins as antiviral factors. 
The classical tumour suppressor induced by IFN is p53, 
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a protein classified as tumour suppressor by its capacity to 
induce cell cycle arrest and apoptosis in response to a 
variety of cellular stresses like DNA damage, transcription 
inhibition, depletion of nucleotide pools, oncogene 
expression, and heat shock, among others (144). The 
induction of p53 by IFN was showed by Takaoka et al. in 
2003, and the antiviral activity of this tumour suppressor 
was reinforced by the fact that it is frequently targeted by 
viral proteins (145). We demonstrated in an elegant way 
that VSV is impaired as a result of apoptosis induction via 
p53 activation, using a mice model expressing an extra-
copy of p53 called “super p53 mice” (146). Although in 
this model we did not directly address the role of PKR in 
the antiviral effect of p53, the close link between both 
proteins described above suggests great potential for PKR 
as a mediator, which should be the subject of other, more 
specific studies. 
The alternative reading frame (ARF) is one of the two 
unrelated products encoded by the INK4a–ARF locus, one 
of the most frequently mutated genes in cancer. Initially, 
ARF activity was linked to p53 stabilisation after 
oncogenic stress, but p53-independent functions have been 
also described, placing this tumour suppressor as sensor of 
different types of stress (147). The control exerted by the 
tumour suppressor Arf on cellular proliferation is crucial to 
restrict tumour development. Several reports described the 
activation of ARF after the expression of viral proteins, 
type I IFN treatment, or after virus infection, suggestive of 
a physiological role for ARF during virus infection (1, 2). 
However, due to the well-known connection between ARF 
and p53, a direct antiviral activity for ARF independently 
of p53 activation had not been considered before. Our 
results revealed that ARF can be induced by viral infection 
and that the expression of ARF reduces viral infectivity. In 
fact, ARF is protective against IFN-sensitive viruses such 
as VSV, Sindbis virus, or a recombinant VV rendered IFN 
sensitive by deletion of the PKR inhibitory gene, E3L. We 
have shown that this antiviral effect depends in part, on 
PKR activation mediated by its release from inhibitory 
complexes with NPM (148). These results provided a new 
link between tumour suppression and antiviral host 
defence, an important step to understand the tumourigenic 
activity of viruses and a crucial learning for the 
forthcoming use of viruses as therapeutic agents. Under 
the direction of Dr Rivas, and in collaboration with Dr 
Esteban and Dr Serrano, these results were published with 
my contribution as the first author in the prestigious 
EMBO Journal in 2006 (148). 
In addition, we suggested other links between tumour 
suppression and antiviral host defence, with PKR playing a 
role in the activation of the NF-kB pathway through viral 
infection. The retinoblastoma protein Rb is a tumour 
suppressor involved in cell cycle control, differentiation, 
and inhibition of oncogenic properties (149). We showed 
that virus replication was increased by the absence of Rb 
tumour suppressor gene expression, and that Rb was 
required for the activation of the NF-kB pathway in 
response to virus infection (150). An analysis of PKR 
activation in Rb knockout and wild-type MEFs in response 
to VSV infection revealed decreased levels of both 
phospho-PKR and phosphor-eI2Fα proteins in the 
knockout cells, suggesting PKR as a possible mediator. 
These results revealed a novel role for tumour suppressor 
Rb in viral infection surveillance and further extend the 
concept of a link between tumour suppressors and antiviral 
activity. These results were published in 2009, under the 
direction of Dr Rivas and Dr Esteban, with my 
contribution as first author in Plos One journal (150).  
In summary, these data highlight an important role of 
different tumour suppressors in the complex innate 
antiviral host defence, due in part to the involvement of 
PKR activity. While the field of tumour suppressors with 
antiviral function is in its infancy, future work will unravel 
a wider significance of tumour suppressors in host cell 
defence against pathogens. Understanding how tumour 
suppressors exert their antiviral function will be relevant in 
the potential use of viruses as oncolytic agents and for 
gene therapy in cancer, as we have reviewed in depth in 
both Carcinogenesis and Future Virology journals (151, 
152). 
4.1.b. PKR as a molecular target of the 5-fluorouracil 
chemotherapeutic drug 
The chemotherapeutic drug 5-FU is widely used in the 
treatment of a range of cancers, being the first and second 
line of treatment in combination in colorectal cancer 
patients, and the third line in the palliative care of 
numerous cancer types. However, adverse effects and 
resistance to the drug remain major clinical problems. 
Since defects in the mediators of apoptosis may account 
for chemoresistance, the identification of new targets 
involved in 5-FU-induced apoptosis is of great clinical 
interest. The p53 tumour suppressor has been reported as 
an important protein involved in 5-FU-induced apoptosis 
(153). However, several works have shown that apoptosis 
can also occur in mutant p53 cell lines by a mechanism 
still unknown, with p53 playing the role of a biomarker of 
response to 5-FU in tumours pending to find new targets 
involved in 5-FU sensibility or resistance. We have 
identified PKR as a key molecular target of 5-FU involved 
in apoptosis induction in human colon and breast cancer 
cell lines (154). We analysed PKR distribution and 
activation, apoptosis induction, and cytotoxic effects 
during 5-FU and 5-FU/IFNα treatment in several colon 
and breast cancer cell lines with different p53 status. PKR 
protein was activated by 5-FU treatment in a p53-
independent manner, inducing phosphorylation of eIF-2α 
and cell death by apoptosis. Furthermore, PKR 
interference promoted a decreased response to 5-FU 
treatment and those cells were not affected by the 
synergistic antitumour activity of 5-FU/IFNα combination. 
We have shown that PKR is activated in absence of p53 
expression and, whereas PKR knockdown decreased 5-
FU-mediated apoptosis, cell death was completely 
abolished in absence of both PKR and p53 proteins. These 
results suggest the importance of both proteins in 5-FU-
induced apoptosis, and the relevance acquired by PKR in 
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tumour cells where p53 is mutated, considering that more 
than 50% of colon tumours are deficient in p53 activity. 
These results, taken together, provide evidence that PKR is 
a key molecular target of 5-FU with potential relevance in 
the clinical use of this drug  (Figure 5), (154). A method of 
obtaining useful data to assess and predict the response to 
treatment with pyrimidine analogues has been protected by 
international patent (155). My contribution in this field 
was as corresponding author of published data in Plos One 
journal in 2011 and the main inventor of the patent. 
Moreover, we have recently published a patent review of 
5-FU derivates from 2012 to 2014 and their implications 
for standard and novel therapies in Expert Opinion on 
Therapeutic Patents journal (157). I am currently the 
principal investigator of two projects funded by the 
Andalusian regional government and the Carlos III 
Institute of Health (ISCIII) whose main objective is to 
analyse the biomarker potential of PKR in patients with 
colon cancer treated with therapies based on 5-FU drugs. 
4.1.c. Novel antitumour drugs with high capacity to induce 
eIF2α phosphorylation and cell death by apoptosis: 
Bozepinib, a promising drug against cancer stem cells, 
induces PKR-mediated apoptosis and synergises with IFN 
Dr Campos, Dr Marchal, Dr Aranega and co-workers 
have a long history designing and researching new 
antitumour drugs that are more effective and less toxic 
than currently standard cancer chemotherapy. My 
contribution to the group actually directed by Dr Marchal 
has helped determine the effectiveness of various drugs to 
induce the phosphorylation of eIF2α and/or PKR-mediated 
apoptosis. Moreover, my experience with IFN has 
contributed to create a new line of research in the group 
that aims to enhance the effectiveness of these novel drugs 
in combination with biological therapies like interferons, 
among others. 
The most studied drug by our group is called Bozepinib 
[(RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-
tetrahydro-4,1- benzoxazepin-3-yl]-9H-purine], which was 
designed by the group directed by Dr Campos at the 
University of Granada (Figure 6), (157). Bozepinib is a 
potent antitumour compound that is able to induce 
apoptosis in breast cancer cells, as we published in 2011, 
showing a 50% inhibitory concentration (IC50) of 0.166 
µM against the MDA-MB-231 human breast 
adenocarcinoma cell line and inducing high levels of 
apoptosis in tumour cells without acute toxicity in mice 
(157). My contribution in 2013 as corresponding author 
and last author of the data published in the Drug Design, 
Development and Therapy journal showed that Bozepinib 
also has antitumour activity in colon cancer cells, showing 
inhibitory concentration (IC50) values 50% lower than 
those described for breast cancer cells, and suggesting 
great potential for this synthetic drug in the treatment of 
cancer (158). We identified PKR as a target of Bozepinib, 
being upregulated and activated by the drug. However, p53 
was not affected and was not necessary for the induction of 
apoptosis in either breast or colon cancer cells. In addition, 
the efficacy of Bozepinib was improved when combined 
with IFNα cytokine, which enhanced Bozepinib-induced 
apoptosis with involvement of protein kinase PKR (Figure 
5). Moreover, we reported for the first time that, in 
combined therapy, IFNα induces a clear process of 
autophagosome formation. Finally, we observed that a 
minor population of caspase 3-deficient MCF-7 breast 
cancer cells persisted during long-term treatment with 
lower doses of Bozepinib and the Bozepinib/IFNα 
combination. Curiously, this population showed β-
galactosidase activity and a percentage of cells arrested in 
S phase, suggesting that tumour cells enter in senescence, 
more evidently so in cells treated with the Bozepinib/IFNα 
combination than in cells treated with Bozepinib or IFNα 
alone. Considering the resistance of some cancer cells to 
conventional chemotherapy, these data suggested that 
combinations enhancing the diversity of the cell death 
outcome might succeed in delivering more effective and 
less toxic chemotherapy (158). 
Given the great potential exhibited by Bozepinib, we 
have recently looked into its mechanism of action with 
very interesting results (159). Bozepinib shows selectivity 
on cancer cells and an inhibitory effect over kinases 
involved in carcinogenesis, proliferation, and 
angiogenesis. The cytotoxic effects of Bozepinib were 
observed in both breast and colon cancer cells expressing 
different receptor patterns. Bozepinib inhibited HER-2 
(human epidermal growth factor receptor 2) signalling 
pathway and JNK (c-Jun-N terminal kinase) and ERKs  
(extracellular signal regulated kinases) kinases. In 
addition, Bozepinib has an inhibitory effect on AKT 
(protein kinase B) and VEGF (vascular endothelial growth 
factor) together with anti-angiogenic and anti-migratory 
activities. Interestingly, Bozepinib inhibited both mammo- 
and colonospheres formation regulating genes related to 
stem properties such as c-MYC, β-CATENIN, SOX2 and 
GLI-3 hedgehog-signalling repressor ,suggesting activity 
against cancer stem-like cells (Figure 5). Finally, 
Bozepinib shows in vivo anti-tumour and anti-metastatic 
efficacy in xenotransplanted nude mice without presenting 
sub-acute toxicity. These findings support the need for 
further studies on the therapeutic potential of Bozepinib 
for cancer patients and were recently published in the 
Oncotarget journal under my leadership as corresponding 
author (159). 
Also designed by the group lead by Dr Campos, other 
purines-derived compounds with antitumour efficacy that 
we have characterised as potent inducers of eIF2α 
phosphorylation and apoptosis include the (R,S)-
Benzofused 1,5-Oxatiepine moiety tethered to purines 
compounds, the (RS)-9-(2,3-dihydro-1,4-benzoxaheteroin-
2- ylmethyl)-9H-purines agents, and several 
enantiospecific heterocycles linked to purines (160-162). 
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Figure 5. PKR is a molecular target of both anticancer drugs, the chemotherapeutic 5-Fluorouracil and the novel compound 
Bozepinib. 5-FU and Bozepinib activates PKR inducing cancer cell death by apoptosis. Whereas 5-FU induces PKR activation in a p53-
independent manner, Bozepinib does not activate p53. Both drugs synergized its antitumour effect in combination with IFNα.. Moreover 
Bozepinib is able to induce atophagy and senescense in cancer cells in combination with IFNα. In addition Bozepinib inhibits both mamo 




Figure 6. Bozepinib structure [(RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1- benzoxazepin-3-yl]-9H-purine]. 
We have previously published Bozepinib structure in Lopez-Cara et al. (157). 
4.2. PKR as a molecular target in neurodegenerative 
diseases  
Alzheimer's disease (AD) is a neurodegenerative 
disorder marked by senile plaques composed of amyloid-β 
(Aβ) peptide, neurofibrillary tangles made of 
hyperphosphorylated T-tau protein, neuronal loss, and 
neuroinflammation, where the apoptotic death 
characterises most of affected neurons. In 2002, 
histological methods showed that activated PKR was 
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accumulated in degenerating neurons in the brain of 
patients with AD (163). Moreover, a number of recent 
studies have implicated PKR in the pathogenesis of other 
neurodegenerative diseases, such as Parkinson's disease, 
Huntington's disease, and amyotrophic lateral sclerosis 
(164-166). Previously, it had been demonstrated that the 
Aβ peptide could induce PKR activation in primary 
neuronal cultures, triggering cell death by apoptosis (131). 
Therefore, PKR activation was considered as a secondary 
consequence of extracellular senile plaque formation 
contributing to neuronal degeneration. However, recent 
evidence indicates a direct involvement of PKR activation 
in the pathology of the disease promoting BACE I 
expression, an enzyme involved in the accumulation of Aβ 
peptide (131, 167). Moreover, PKR is also involved in the 
mechanism of senile plaque formation through tau 
phosphorylation via glycogen synthase kinase 3β (GSK- 
3β) activation (168). On the other hand, PKR seems to be 
involved in the inflammatory process that has been 
suggested to contribute to AD (131, 169). Several works 
have shown how PKR inhibition prevented the neuronal 
loss by apoptosis, suggesting the high potential of PKR as 
a therapeutic target in neurodegenerative diseases (131, 
169). In addition, data showing PKR involvement in 
learning and memory suggest that PKR inhibition could 
benefit humans, especially those experiencing age-related 
memory loss or the most devastating memory loss 
associated with AD (170). Although different chemical 
compounds and specific peptides protect neurons from 
apoptosis by inhibiting PKR, unfortunately they also 
display high toxicity, induce undesirable effects outside 
the nervous system, or are not able to cross the blood brain 
barrier (131, 169). It is therefore necessary to continue 
looking for new specific inhibitors of PKR. Due to the fact 
that PKR is an ubiquitous and multifunctional protein, the 
knowledge of the components involved in how and why 
PKR is more active in these pathologies would help find 
alternative drugs to target the abnormal activation of PKR 
and contribute to the therapeutic control of 
neurodegenerative diseases. 
4.3. Is PKR involved in inflammatory diseases? 
Since PKR is induced by IFNα and the 
proinflammatory NF-kB transcription factor is a target of 
the kinase, its involvement in inflammatory processes has 
been suggested in several works (1, 2). In fact, 
experiments using primary mouse cocultures containing 
neurons, astrocytes, and microglia have shown that 
inhibition of PKR prevents activation of NF-kB, as well as 
a strong decrease in production and release of tumour 
necrosis factor-α (TNF-α) and interleukin-1b (IL-1b), 
(171). Several studies have shown a significant increase in 
various inflammatory mediators in plasma and peripheral 
blood mononuclear cells of patients with AD compared to 
age-matched controls (172). Interestingly, levels of both 
total PKR and phospho-PKR were modified in blood 
lymphocytes of patients with AD compared with control 
individuals, and the upregulation of these proteins in 
cerebrospinal fluid was suggested as a potential biomarker 
for AD (131, 169). 
Moreover, NFkB regulates the cytokines involved in 
several inflammatory diseases like rheumatoid arthritis and 
lupus erythematosus, such as IL-6, TNF-α, and IL-1. The 
kinase PKR has been involved in the induction of TNF-α 
and IL-6 in response to lipopolysaccharide (LPS) in 
fibroblasts and alveolar macrophages (173). Interestingly, 
transcription of IL-1β, TNF-α and IL-6 decreased in mice 
deficient in the expression of PKR when subjected to a 
high-fat diet (174). The inhibition of PKR with the C16 
compound in PBMCs isolated from patients significantly 
decreased the expression and production of cytokines IL-
1β, TNF-α, and IL-6, suggesting that the inhibition of PKR 
at the peripheral level can decrease the inflammatory 
process in Alzheimer's patients (172). However, the effect 
of PKR inhibition over these cytokines in autoimmune 
diseases has not yet been explored.  
Recently, it has been shown that PKR is an important 
key element of the inflammasome complex in 
macrophages. PKR interacts with the NOD-like receptor 
family, which, together with caspase 1 (Casp-1), integrates 
this interesting complex, inducing high levels of the 
HMGB1 cytokine (175). High levels of this cytokine and 
of IL -1β have also been linked with inflammatory 
processes involved in AD, autoimmune diseases, and 
cancer (131). In addition, the PKR gene deletion, or 
specific drug inhibition, severely diminished 
inflammasome activation in response to various stimuli 
(131). Therefore, the analysis of PKR in cancer, 
neurodegeneration, and autoimmune diseases in the 
context of the inflammasome complex can provide new 
evidence on the connection of PKR with these pathologies 
with an interesting therapeutic potential. 
5. CONCLUDING REMARKS AND FUTURE 
PROSPECTS 
Since PKR was discovered, its mechanism of action 
has been gradually brought to light in several international 
publications, an effort to which we have made important 
contributions. The involvement of PKR in interferon-
mediated activities, in the induction of apoptosis, in the 
activation of proinflammatory transcription factor NFkB, 
along with its role in signalling pathways linking 
numerous biological events which include antiviral 
defence and cell growth, are clear indicators of the great 
potential that this protein may have in a variety of 
pathologies (Figure 7). The identification of PKR as a 
target of both conventional chemotherapeutic and novel 
drugs highlights the need to carry out translational studies 
with patients to validate its potential as a biomarker of 
important diseases like cancer and neurodegeneration. 
Moreover, the PKR deregulation showed in diseases like 
Alzheimer and inflammatory processes underlines the need 
to find applicable inhibitors of this kinase. Since PKR is 
expressed in almost all cells, its therapeutic potential could 
arise from the factors involved in its regulation. In fact, 
understanding the cellular factors and signals that regulate 
the role of PKR in the different diseases would be 
extremely valuable from a clinical point of view. 
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The present review has shown the importance to 
conduct continued basic molecular and preclinical studies. 
Further along the road, clinical studies could show how an 
application could be made to diagnostics and 
pharmacology. With personalised medicine looming in the 
future and the genetic and proteomic background of each 
patient determining specific approaches, PKR could play 
an extremely relevant clinical role. 
 
Figure 7. Representative diagram of PKR activation and modulation: pathological consequences of an unbalanced PKR activity. 
PKR is activated by a variety of cellular stresses including viral and bacterial infections, cytokines, and chemotherapeutic drugs. PKR 
activation involves its autophosphorylation, which triggers the phosphorylation of translation initiation factor eIF2α and the activation of 
the proinflammatory NF-kB transcription factor. Both effects contribute to induce apoptosis cell death or to induce cell proliferation 
depending on the stimulus and unknown factors. In addition, PKR is involved in inflammasome activation and cytokines liberation as IL-
6, TNF α and HMGB among others. Moreover PKR is involved in various pathways that engage multiple genes, including MAPKs, 
ATFs, STATs, and p53, among others. Diverse PKR modulators have been identified, highlighting the PKR activator PACT, the inhibitor 
TRBP, and the microRNA mir886. An unbalanced effect induced by dysregulated PKR activity could contribute to neurodegeneration, 
cancer and inflammatory diseases. 
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